Choose your reading level
In plain language
CT20p is an experimental peptide studied as a way to interfere with machinery that helps proteins fold inside cells. Researchers reported effects in cancer models; those results are not proof of a cancer treatment for people. (Bassiouni et al., 2016) (Cox et al., 2022)
Structure and mechanism
The 20-residue candidate comes from the C-terminal region of Bax. Researchers identified CCT/TRiC as an intracellular target and found associations between CCT abundance, cytoskeletal changes and susceptibility to nanoparticle-delivered CT20p in tested cell lines. (Bassiouni et al., 2016)
Mechanistic support and limits
Pull-down and CCT perturbation experiments support target involvement but do not fully resolve the inhibitory mechanism. Observational tumor-tissue findings are distinct from therapeutic trials, and the later neuroblastoma work reports cell-culture treatment experiments, not clinical benefit. (Bassiouni et al., 2016) (Cox et al., 2022)
What the cited studies establish
Breast cancer models and tissue observations
The 2016 study investigated CCT binding, cytoskeletal changes and susceptibility in cell models, together with tumor-tissue expression and survival associations. Its mouse metastasis work examined CCT expression; the human tissue findings do not show CT20p treatment of patients. (Bassiouni et al., 2016)
Neuroblastoma cell research
The 2022 paper reports nanoparticle-delivered CT20p cytotoxicity in cultured IMR-32 cells. The study also examined CCT2 as a possible diagnostic indicator, including an artificial spiked-blood experiment rather than a validated patient test. (Cox et al., 2022)
Evidence and safety boundaries
These papers do not establish human treatment benefit, a safe clinical regimen or a validated companion diagnostic. Formulation and delivery matter: results from a peptide–nanoparticle system should not be generalized to a different product. (Bassiouni et al., 2016) (Cox et al., 2022)
This profile does not claim a currently recruiting clinical trial or a regulatory approval. Those require separate current verification; no dosing, sourcing or self-experimentation guidance is provided.
Research attribution and interests
The work includes Annette Khaled and collaborating researchers, and the UCF laboratory lists CT20p research among its projects. The 2016 paper discloses patent interests involving authors Annette R. Khaled and Jesus M. Perez. (Bassiouni et al., 2016) (UCF Khaled laboratory projects)
No researcher or university is presented as a VALREXA adviser, collaborator or reviewer. No independent expert review of this profile is claimed.
Sources and further reading
Educational information only, not medical advice or a treatment recommendation. Report a correction.